Acute Myeloid Leukemia Market Size & Share, by Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic); Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy); Route of Administration (Oral, Parenteral); End Users (Hospitals, Homecare, Specialty Centers): Distribution Channel (Hospital, Online, Retail Pharmacy); Regimen (DC, AVD, VCD) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 2894
  • Published Date: May 24, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Acute Myeloid Leukemia Market size was valued at USD 2 Billion in 2023 and is poised to exceed USD 7 Billion by the end of 2036, registering over 10% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of acute myeloid leukemia is estimated at USD 3 Billion.

The number of acute myeloid leukemia patients is rising owing to the aging population across the globe. Like many other malignancies, acute myeloid leukemia (AML) is a hematological neoplasm that typically affects the elderly, with a median age of presentation of 67 years.

According to the World Health Organization (WHO), the number of individuals 60 years of age and over will double (to 2.1 billion) worldwide by 2050.


Acute Myeloid Leukemia Market
Get more information on this report: Request Free Sample PDF

Acute Myeloid Leukemia Sector: Growth Drivers and Challenges

Growth Drivers

  • Integration of personalized medicine - In acute myeloid leukemia, precision medicine is used by molecular profiling to identify specific genetic mutations and unique biomarkers for each patient.

    To achieve a more personalized and precise approach to AML management, information guides the selection of targeted therapies and tailored treatment plans, optimizing the effectiveness of interventions and minimizing adverse reactions.

    According to a study conducted four years ago by The Leukemia & Lymphoma Society (LLS), patients with acute myeloid leukemia (AML) who received precision medicine had better survival outcomes and a much lower early death rate and fared far better than individuals who started therapy early in life.
  • Development of advanced treatment options - Several research studies are being carried out to show the medications' efficacy, thus resulting in the development of advanced treatment options with a better understanding of acute myeloid leukemia (AML).

    For instance, research named 'Daunorubicin or Idarubicin with Cytarabine Plus Quizartinib vs. Physician's Selection in Newly Acquired FLT3-ITD+ AML (Q-SOC)' is now in Phase III clinical trials, according to the United States National Library of Medicine.

Challenges

  • Lack of awareness and education - There may still be gaps in knowledge and understanding between healthcare professionals, patients, and the public despite efforts to increase awareness about AML. Delayed diagnosis, insufficient treatment decisions, and poor patient outcomes can be associated with low awareness.
  • Resistance to conventional therapies - Due to a high percentage of treatment failure brought on by an increase in the prevalence of medication resistance that causes disease relapse, AML continues to be the primary cause of leukemia-related mortality.

    Relapsed and refractory AML is linked to a poor prognosis because of an inadequate response to traditional antileukemic therapy led by the altered-functioning proteins and enzymes, signaling pathway dysregulation, mutations in cell cycle control genes, epigenetic modifiers, and microRNA.

Acute Myeloid Leukemia Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

10%

Base Year Market Size

USD 2 billion

Forecast Year Market Size

USD 7 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Acute Myeloid Leukemia Segmentation

Treatment Type [Chemotherapy (Cytarabine, Anthracycline Drugs, Alkylating Agents, Anti-metabolites, Tyrosine Kinase Inhibitors, Hormonal Therapy), Targeted Therapy, Immunotherapy, Hormone Therapy]

Chemotherapy segment is estimated to capture over 62% acute myeloid leukemia market share by 2036. Chemotherapy is significantly utilized for the solidification treatment of acute myeloid leukemia. Owing to its effectiveness in curing AML the cytarabine is massively utilized during chemotherapy.

According to organizations working in the field of cancer, cytarabine a type of chemotherapy drug is more efficient at treating acute myeloid leukemia and that's why it gets so much use.

The growth of this market is also expected to be driven by an increase in US Food and Drug Administration approval for cytarabine as a treatment for acute myelodysplastic syndrome.

For instance, in March 2021 Jazz Pharmaceuticals plc announced that it received approval from the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (daunorubicin and cytarabine) to add a new indication for the treatment of children patients one year of age and older with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related alterations to advance cancer research and concentrating on the individuals who can benefit from it most.

End Users (Hospitals, Homecare, Specialty Centers)

Hospital segment in the acute myeloid leukemia market is poised to grow at over 10% CAGR between 2024 and 2036. The growth can be accredited to the growing healthcare industry. Several countries across the globe are investing in the development of healthcare infrastructure, leading to improvement in cancer treatment, and diagnostic facilities through earlier detection and treatment of acute myeloid leukemia disease.

More and more hospitals around the world are being equipped with advanced facilities to provide AML patients with integrated care. In addition, screening, and treatment facilities are provided to the patients under one roof in hospitals.

For instance, by 2026, it is anticipated that the healthcare sector in India will generate more than USD 600 billion.

Disease Type (Myeloblastic, Promyelocytic, Myelomonocytic)

Myeloblastic segment is expected to dominate over 40% acute myeloid leukemia market share by 2036. This growth of the segment is set to be encouraged by the growing pediatric population. Acute myeloblastic leukemia, the second most common type of leukemia in children, is a malignant disorder where the bone marrow creates an enormous amount of abnormal blood cells and has the worst prognosis of all childhood cancers.

According to estimates, more than 20% of people on the planet are under the age of 15.

Our in-depth analysis of the market includes the following segments:

          Disease Type

  • Myeloblastic
  •  Promyelocytic
  • Myelomonocytic

           Treatment Type

  • Chemotherapy
  • Cytarabine
  • Anthracycline Drugs
  • Alkylating Agents
  • Anti-metabolites
  • Tyrosine Kinase Inhibitors
  • Hormonal Therapy
  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy

          Route of Administration

  • Oral
  • Parenteral

          End Users

  • Hospitals
  • Homecare
  • Specialty Centers

           Distribution Channel

  • Hospital
  • Online
  • Retail Pharmacy

           Regimen

  • DC
  • AVD
  • VCD

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Acute Myeloid Leukemia Industry - Regional Synopsis

North American Market Forecasts

North America in acute myeloid leukemia market is estimated to hold over 40% revenue share by the end of 2036. The growth of this market in the region will be impelled by the growing R&D and product launches. This has led to the discovery of more effective therapies in the field of acute myeloid leukemia.

Besides this, the increasing incidence of acute myeloid leukemia in the United States is likely to drive market expansion. For instance, there were 60,650 new instances of leukemia cancer in the US in 2022, with 24,000 of those cases projected to result in death.

Canada has progressively increased AML incidence rates, with an estimated average of 30.61 cases per million people per year.

APAC Market Statistics

The Asia Pacific acute myeloid leukemia market is set to grow significantly during the period between 2024-2036. There is an increasing prevalence of AML in the region on account of population growth. As a result, there is a growing acceptability of novel treatments and therapies leading to more people obtaining timely therapy.

As per UNFPA, approximately 4.3 billion people, or 60% of the world's population, live in the Asia and Pacific area.

China is home to one in five children worldwide who suffer from acute lymphoblastic leukemia, and more than 55% of the 75.3 thousand new cases of leukemia in China each year are AML patients.

The majority of adult leukemia cases in Korea are caused by acute myeloid leukemia (AML), a representative blood malignancy, which has been a significant national public health concern.

Substantial progress has been made recently in the identification and management of AML in Japan, leading to the generation of a need for novel and more potent AML treatments. AML and other diseases such as multiple myeloma are key areas of attention for the Japanese government, which is constantly trying to improve access to current medications while also sponsoring research into novel AML treatments.

Research Nester
Acute Myeloid Leukemia Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Acute Myeloid Leukemia Landscape

    The acute myeloid leukemia market consists of several key players who are launching various strategic initiatives to expand their market position in the acute myeloid leukemia industry. 

    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis International AG
    • Celgene Corporation
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • AbbVie Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline plc
    • Sanofi-Aventis (Genzyme Corporation)
    • Sunesis Pharmaceutical Inc.

In the News

  • Novartis International AG announced that it was successfully acquiring Cadent Therapeutics, a biotechnology company in clinical development for the manufacture of medicines for nervous and psychiatric diseases. The objective of this acquisition was to expand the range of medicines provided by Novartis for cancer and gene therapy, in particular AML therapies.
  • Bristol-Myers Squibb announced that its product, Onureg, had been approved by the FDA for maintenance therapy of AML in patients who were completely cured after aggressive chemotherapy. This medicine is the first and only oral medicine to be approved by the FDA for this use.

Author Credits:  Radhika Pawar


  • Report ID: 2894
  • Published Date: May 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of acute myeloid leukemia was over USD 2 billion.

The market size for acute myeloid leukemia is projected to cross USD 7 billion by the end of 2036 expanding at a CAGR of 10% during the forecast period i.e., between 2024-2036.

The major players in the market are Novartis International AG, Celgene Corporation, Bristol-Myers Squibb Company, Amgen Inc., AbbVie Inc., Eli Lilly and Company, GlaxoSmithKline plc, Sanofi-Aventis (Genzyme Corporation), Sunesis Pharmaceutical Inc., and others.

In terms of treatment type, the chemotherapy segment is anticipated to account for the largest market share of 62% during 2024-2036.

The North America acute myeloid leukemia sector is poised to hold the highest share of 40% by 2036.
Acute Myeloid Leukemia (AML) Treatment Market Report Scope
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample